Market launch of the nasal adrenaline spray, neffy®, for treatment of adults and children with severe allergies in Canada

ALK-Ábelo announced the Canadian market launch of neffy®, a first-in-class nasal adrenaline spray for emergency anaphylaxis treatment. Approval from Health Canada in April 2026 preceded this commercial milestone, marking the company's expansion into a differentiated therapeutic category addressing a critical unmet need in emergency allergy care.

The product targets both adults and children weighing ≥30 kg across multiple anaphylaxis triggers—food, insect venom, medications, and exercise-induced reactions. This addresses a significant patient population with limited non-injectable emergency options, potentially creating a competitive moat around ALK-Ábelo's portfolio. The nasal delivery mechanism improves accessibility compared to traditional intramuscular epinephrine auto-injectors, potentially driving adoption across both institutional and consumer channels.

The Canadian launch represents an early-market foothold in North America for a product with multi-market potential. Success in Canada could validate the commercial thesis for geographic expansion to the U.S. and other developed markets, though regulatory and reimbursement timelines remain material execution risks. Revenue contribution timing and penetration rates will determine materiality to near-term results.

Sector implication: This launch validates novel delivery mechanisms in specialty pharmaceutical markets. The success of neffy® could incentivize investment in non-traditional formulation approaches across immunology and emergency care, benefiting the broader Health Care sector's innovation narrative without materially impacting near-term broad-market correlations.